Karyopharm Therapeutics Inc. (KPTI) — SEC Filings
Karyopharm Therapeutics Inc. (KPTI) — 50 SEC filings. Latest: ARS (Apr 13, 2026). Includes 27 8-K, 9 SC 13G/A, 6 10-Q.
View Karyopharm Therapeutics Inc. on SEC EDGAR
Overview
Karyopharm Therapeutics Inc. (KPTI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 27, 2026: Karyopharm Therapeutics Inc. filed an 8-K on March 27, 2026, to report other events. The filing does not contain specific financial figures or new material events beyond the reporting requirement.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 3 bearish, 45 neutral, 2 mixed. The dominant filing sentiment for Karyopharm Therapeutics Inc. is neutral.
Filing Type Overview
Karyopharm Therapeutics Inc. (KPTI) has filed 1 ARS, 27 8-K, 6 10-Q, 3 DEF 14A, 9 SC 13G/A, 3 SC 13G, 1 10-K with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of KPTI's 34 recent filings, 2 were flagged as high-risk, 16 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $111,988,000 |
| Net Income | -$93,800,000 |
| EPS | -$10.93 |
| Debt-to-Equity | N/A |
| Cash Position | $45,900,000 |
| Operating Margin | N/A |
| Total Assets | $96,232,000 |
| Total Debt | $210,000,000 |
Key Executives
- Newton, Massachusetts
- Chief Executive Officer
- Dr. Jonathan G. Kolitz
- Dr. John G. Simon
- Ms. Sarah L. Kelly
- Dr. John J. O'Malley
- Michael W. Yothers
- Dr. Jonathan M. Kay
- Dr. David M. Roth
- Mr. Paulson
- Dr. Kauffman
Industry Context
Karyopharm Therapeutics operates in the highly competitive biopharmaceutical industry, focusing on developing novel therapies for cancer and other serious diseases. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often depends on the ability to bring innovative drugs to market and secure market access against established players and emerging biotech firms.
Top Tags
financial-condition (5) · corporate-governance (4) · 10-Q (4) · sec-filing (3) · Biotechnology (3) · financials (3) · filing (3) · management-change (3) · financial-reporting (3) · Karyopharm Therapeutics (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss for Nine Months Ended Sep 30, 2025 | $93.8M | Increased from $45.6M in prior year, primarily due to absence of debt extinguishment gain. |
| Cash, Cash Equivalents and Investments as of Sep 30, 2025 | $45.9M | Significant decrease from $108.7M at Dec 31, 2024, contributing to going concern doubt. |
| Accumulated Deficit as of Sep 30, 2025 | $1.7B | Indicates substantial historical losses and financial strain. |
| Workforce Reduction | 20% | Announced July 11, 2025, as part of cost management efforts. |
| Total Revenue for Nine Months Ended Sep 30, 2025 | $112.0M | Slight decrease from $114.7M in prior year. |
| Research and Development Expenses for Three Months Ended Sep 30, 2025 | $30.5M | Decreased by 15.5% from $36.1M in prior year, reflecting cost controls. |
| Basic Net Loss Per Share for Nine Months Ended Sep 30, 2025 | $10.93 | Increased from $5.68 in prior year, reflecting higher net loss. |
| Shares of Common Stock Outstanding as of Oct 30, 2025 | 17,050,876 | Reflects the 1-for-15 reverse stock split. |
| Total Revenue | $34.7M | Decreased from $38.9M in Q2 2024, indicating top-line pressure. |
| Product Revenue | $29.8M | Down from $33.6M in Q2 2024, highlighting challenges for XPOVIO. |
| Net Loss | $45.2M | Improved from $55.1M in Q2 2024, driven by cost reductions. |
| R&D Expenses | $30.1M | Decreased from $38.5M in Q2 2024, reflecting cost control efforts. |
| SG&A Expenses | $35.8M | Reduced from $40.2M in Q2 2024, contributing to a narrower net loss. |
| Convertible Senior Notes | $150.0M | Principal amount due 2025, a significant near-term financial obligation. |
| Shares Sold | 1,300,000 | Through ATM offering, generating $4.0M in net proceeds. |
Forward-Looking Statements
- {"claim":"Karyopharm Therapeutics Inc. stock price may experience downward pressure due to the institutional divestment.","entity":"Karyopharm Therapeutics Inc.","targetDate":"Q1 2024","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Karyopharm Therapeutics Inc. (KPTI)?
Karyopharm Therapeutics Inc. has 50 recent SEC filings from Jan 2024 to Apr 2026, including 27 8-K, 9 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of KPTI filings?
Across 50 filings, the sentiment breakdown is: 3 bearish, 45 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Karyopharm Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Karyopharm Therapeutics Inc. (KPTI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Karyopharm Therapeutics Inc.?
Key financial highlights from Karyopharm Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for KPTI?
The investment thesis for KPTI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Karyopharm Therapeutics Inc.?
Key executives identified across Karyopharm Therapeutics Inc.'s filings include Newton, Massachusetts, Chief Executive Officer, Dr. Jonathan G. Kolitz, Dr. John G. Simon, Ms. Sarah L. Kelly and 6 others.
What are the main risk factors for Karyopharm Therapeutics Inc. stock?
Of KPTI's 34 assessed filings, 2 were flagged high-risk, 16 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Karyopharm Therapeutics Inc.?
Recent forward-looking statements from Karyopharm Therapeutics Inc. include guidance on {"claim":"Karyopharm Therapeutics Inc. stock price may experience downward pressure due to the institutional divestment..